American Journal of Hematology

Article	Citations
Hematological findings and complications of COVID‐19	1214
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management	486
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	310
Thrombosis in COVID‐19	219
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring	217
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	210
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management	203
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management	186
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures	151
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management	139
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies	137
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine	125
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management	114
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis	113
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA	107
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy	105
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management	101
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure	96
Morphological anomalies of circulating blood cells in COVID‐19	95
Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment	95
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study	92
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine	89
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center	88
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients	81
Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab	81

Critically ill COVID‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability	76
Acute myeloid leukemia: 2021 update on risk‐stratification and management	73
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management	71
Leukoerythroblastic reaction in a patient with COVID‐19 infection	71
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring	71
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	68
Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19)	67
Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism	67
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab	66
Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management	66
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY	65
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma	62
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation	61
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality	59
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management	59
COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient	57
COVID‐19 and mycoplasma pneumoniae coinfection	55
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management	54
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment	53
Recommendations for diagnosis and treatment of methemoglobinemia	52
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients	51
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	51
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1	51
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients	50
Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome	50
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life	49
Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction	49
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management	49
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes	48
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments	48
SARS‐CoV‐2 infection in beta thalassemia: Preliminary data from the Italian experience	47
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma	46
The first case of acquired hemophilia A associated with SARS‐CoV‐2 infection	46
Increased blood viscosity and red blood cell aggregation in patients with COVID‐19	45
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	45
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases	44
The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia	43
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine	43
Granulocyte‐colony stimulating factor in COVID‐19: Is it stimulating more than just the bone marrow?	42
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study	41
Hematologic parameters in patients with COVID‐19 infection: a reply	41
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event	40
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients	39
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	39
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	39
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report	39
Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease	39
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of Eu	38
High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicen	37
2021 clinical trials update: Innovations in hemophilia therapy	37

2021 update on clinical trials in β‐thalassemia	37
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management	36
Heparin induced thrombocytopenia antibodies in Covid‐19	36
COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study	36
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies	35
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors	35
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist	34
Plasmacytoid lymphocytes in SARS‐CoV‐2 infection (Covid‐19)	34
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial	34
Blood and blood product use during COVID‐19 infection	34
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study	34
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study	32
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping	31
Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib	30
Real‐Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT‐HU cohort study	30
Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis	29
Cell‐type‐specific insights into iron regulatory processes	29
Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT	29
Prognostic factors and long‐term follow‐up of basiliximab for steroid‐refractory acute graft‐versus‐host disease: Updated experience from a large‐scale study	29
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach	29
Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 u	29
Expert‐level automated malaria diagnosis on routine blood films with deep neural networks	28
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia	28
Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia	28
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis	28
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms	27
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia	27
Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later	27
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic	27
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate	27
Large granular lymphocytic leukemia – A retrospective study of 319 cases	26
Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK/T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study	26
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management	26
Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival	25
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data	25
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond	25
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes	25
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease	25
Familial thrombocytopenia flare‐up following the first dose of mRNA‐1273 Covid‐19 vaccine	25
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy	25
Gene therapies for transfusion dependent β‐thalassemia: Current status and critical criteria for success	24
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression	24
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis	24
Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma	24
Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry	24
Circulating endothelial cells in COVID‐19	24
The emergence of methemoglobinemia amidst the COVID‐19 pandemic	24
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	24
Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study	24
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies	24
Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma	23
Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact	23
Myeloid and lymphoid vacuolation in VEXAS syndrome	23
Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria	23
Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update	23
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option	23
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia	23
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure af	23
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients	23
Patient‐reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium	23
Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia	23
Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management	22
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations	22
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐c	22
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL‐1308 trial	22
2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management	22
Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia	22
Follicular lymphoma: 2023 update on diagnosis and management	22
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results	21
Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients	21
Optical genome mapping for structural variation analysis in hematologic malignancies	21
Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease	21
Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study	21
An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology	21
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors	21
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label study	21
Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination	21
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients	21
Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study	21
Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study	21

Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study	20
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy	20
Role of imaging in multiple myeloma	20
Glucose‐6‐phosphate dehydrogenase deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine	20
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	20
SARS‐CoV‐2 vaccination in patients with autoimmune cytopenias: The experience of a reference center	20
Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID‐19)	20
Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations	20
Genomic characteristics and prognostic significance of co‐mutated ASXL1/SRSF2 acute myeloid leukemia	20
Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban	20
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials	20
The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations	20
Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias	20
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost	20
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management	19
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event	19
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes	19
Current approaches to management of high‐risk multiple myeloma	19
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients	19
Risk of mortality from anemia and iron overload in nontransfusion‐dependent β‐thalassemia	19
Ecarin based coagulation testing	19
Risk factors for severe COVID‐19 in hospitalized sickle cell disease patients: A study of 319 patients in France	19
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes	19
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis	19
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice	19
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management	19
Vaccine‐induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism	19
Viscoelastic hemostatic assays: Update on technology and clinical applications	19
Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents	19
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial	18
The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States	18
Iron and platelets: A subtle, under‐recognized relationship	18
Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study	18
CD34+ cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem ce	18
Current approaches to management of newly diagnosed multiple myeloma	18
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) c	18
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease	18
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	18
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses	18
Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH	18
Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment	18
Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution	18
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival	18
Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease	17
Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib	17
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia	17
Daratumumab for disabling cold agglutinin disease refractory to B‐cell directed therapy	17
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond the CLL international prognostic index	17
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia	17
An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia	17
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	17
Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia	17
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins	17
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study	17
Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study	17
Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study	17
Immune thrombocytopenia due to COVID‐19 during pregnancy	17
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease	17
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study	16
CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia	16
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm	16
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions	16
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease	16
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other co	16
Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts	16
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia	16
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry	16
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis	16
The benefits of iron supplementation following blood donation vary with baseline iron status	16
From Hematologistʼs desk: The effect of COVID‐19 on the blood system	16
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	16
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts	16
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance	15
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the	15
Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study	15
Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years	15
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs	15
Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation	15
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	15
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403	15
Adoptive therapy with cytomegalovirus‐specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy	15
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia	15
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma	15
Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma	15
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	15
Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts	14
Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting	14
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	14
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen	14
Plasma P‐selectin is an early marker of thromboembolism in COVID‐19	14
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio	14
Chimeric antigen receptor T‐cells safety: A pharmacovigilance and meta‐analysis study	14
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival	14
The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapy	14
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study	14